
## Hui-Ming Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9523454/publications.pdf Version: 2024-02-01



HUL-MING LIN

#	Article	lF	CITATIONS
1	Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2022, 40, 154-154.	0.8	1
2	Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 2022, 14, 1708.	1.7	6
3	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 2022, 20, 112.	2.3	6
4	Patient-derived explant model of appendiceal cancer Journal of Clinical Oncology, 2022, 40, 4160-4160.	0.8	0
5	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 860-870.	2.0	14
6	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 2021, 72, 103625.	2.7	23
7	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4964.	1.7	13
8	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 2019, 76, 306-312.	0.9	26
9	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. Molecular Cancer Research, 2019, 17, 949-962.	1.5	65
10	Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2019, 37, 230-230.	0.8	2
11	Effect of FAK inhibitor VSâ€6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate, 2018, 78, 308-317.	1.2	48
12	MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Scientific Reports, 2018, 8, 7820.	1.6	33
13	Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 2017, 116, 1002-1011.	2.9	48
14	A distinct plasma lipid signature associated with poor prognosis in castrationâ€resistant prostate cancer. International Journal of Cancer, 2017, 141, 2112-2120.	2.3	54
15	The plasma lipidome in castration-resistant prostate cancer Journal of Clinical Oncology, 2017, 35, 5055-5055.	0.8	0
16	Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 5014-5014.	0.8	0
17	Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 5039-5039.	0.8	1
18	Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 190-201.	1.9	42

Hui-Ming Lin

#	Article	IF	CITATIONS
19	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer Journal of Clinical Oncology, 2014, 32, 44-44.	0.8	0
20	Metabolomic analysis reveals differences in urinary excretion of kiwifruitâ€derived metabolites in a mouse model of inflammatory bowel disease. Molecular Nutrition and Food Research, 2011, 55, 1900-1904.	1.5	10
21	Using metabolomic analysis to understand inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 1021-1029.	0.9	56
22	Identification of Urinary Biomarkers of Colon Inflammation in IL10 <sup>-/-</sup> Mice Using Short-Column LCMS Metabolomics. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	19
23	Metabolomic Analysis Identifies Inflammatory and Noninflammatory Metabolic Effects of Genetic Modification in a Mouse Model of Crohn's Disease. Journal of Proteome Research, 2010, 9, 1965-1975.	1.8	64
24	Nontargeted Urinary Metabolite Profiling of a Mouse Model of Crohn's Disease. Journal of Proteome Research, 2009, 8, 2045-2057.	1.8	59